Clinical Report: More Good Than Harm

Overview

Sustained-release intracameral implants, such as Durysta and iDose TR, offer significant benefits in managing glaucoma by improving patient adherence and quality of life. These implants provide a procedural approach to treatment, minimizing the burdens associated with topical medications.

Background

Glaucoma management often relies on topical medications, which can lead to issues such as non-adherence and side effects. The introduction of sustained-release intracameral implants represents a shift towards more effective treatment options that can enhance patient outcomes. Understanding the clinical and logistical aspects of these implants is crucial for optimizing patient care.

Data Highlights

No specific numerical data provided in the article.

Key Findings

• Durysta and iDose TR are FDA-approved for all stages of open-angle glaucoma and ocular hypertension.
• Durysta lasts typically 6 to 9 months after a single administration, while iDose TR can last 1 to 2 years.
• Both implants can be administered with minimal disruption to clinic flow.
• Postoperative care is streamlined, with follow-up visits tailored to individual patient needs.
• Proper documentation is essential for insurance coverage and billing processes.

Clinical Implications

Ophthalmologists should consider incorporating sustained-release implants into their practice to improve patient adherence and reduce the burden of topical medications. Training staff on the procedural aspects and billing nuances is essential for successful implementation.

Conclusion

Sustained-release intracameral implants represent a promising advancement in glaucoma management, offering both clinical efficacy and improved patient quality of life.

References

1. American Journal of Epidemiology, 2024 -- A Response to 'Reevaluating Positive Epidemiology'
2. The ASCO Post, 2014 -- Overutilization a Key Target in Efforts to Control Health-Care Costs
3. European Glaucoma Society – Terminology and guidelines for glaucoma, 6th Edition | British Journal of Ophthalmology
4. Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial
5. Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2) - PMC
6. The ASCO Post — Overutilization a Key Target in Efforts to Control Health-Care Costs
7. Ophthalmology Management — As I See It
8. European Glaucoma Society – Terminology and guidelines for glaucoma, 6th Edition | British Journal of Ophthalmology
9. Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial
10. Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2) - PMC